TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Fast Muscle Activation and Stepping Training (FAST) on Balance and Mobility Post-stroke
Brief Summary: The purpose of this study is to determine whether FAST (Fast muscle Activation and Stepping Training) exercises will improve walking balance in individuals after stroke to a greater extent than usual care.

Hypothesis: The primary hypothesis is that improvements in walking balance will be larger following 12 sessions of FAST exercise retraining compared to usual care in persons in the sub-acute phase after stroke.


Options:
A: Arm Label: ICoreDIST; Type: EXPERIMENTAL; Interventions: Procedure: ICoreDIST | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Care | Intervention Type: PROCEDURE; Name: ICoreDIST; Assigned to Arm(s): ICoreDIST | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): Standard Care
B: Arm Label: Flywheel leg-press resistance exercise; Type: EXPERIMENTAL; Interventions: Other: Flywheel leg-press resistance exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Flywheel leg-press resistance exercise; Assigned to Arm(s): Flywheel leg-press resistance exercise
C: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: FAST protocol; Type: EXPERIMENTAL; Interventions: Behavioral: FAST protocol | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: FAST protocol; Assigned to Arm(s): FAST protocol
D: Arm Label: With isokinetic strength training; Type: EXPERIMENTAL; Interventions: Other: isokinetic strength training | Arm Label: without isokinetic strength training; Type: PLACEBO_COMPARATOR; Interventions: Other: passive motion | Intervention Type: OTHER; Name: isokinetic strength training; Assigned to Arm(s): With isokinetic strength training | Intervention Type: OTHER; Name: passive motion; Assigned to Arm(s): without isokinetic strength training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The GREEN (Growing Right: Eating Eco-Friendly & Nutritious) Project Lunch Box Study
Brief Summary: The central hypothesis of The GREEN Project Lunch Box Study is that a school-based communication campaign that combines healthy eating and eco-friendly messages will improve the quality of foods that children bring from home to school more than a healthy eating campaign alone and compared to a control/delayed intervention condition at the end of one school year.


Options:
A: Arm Label: Healthy Eating + Eco-Friendly Campaign; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Eating + Eco-Friendly Campaign | Arm Label: Healthy Eating Campaign; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Eating Campaign | Arm Label: Control/Delayed Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy Eating + Eco-Friendly Campaign; Assigned to Arm(s): Healthy Eating + Eco-Friendly Campaign | Intervention Type: BEHAVIORAL; Name: Healthy Eating Campaign; Assigned to Arm(s): Healthy Eating Campaign
B: Arm Label: Mobile phone based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile phone based intervention; Assigned to Arm(s): Mobile phone based intervention
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Chef; Type: EXPERIMENTAL; Interventions: Other: Chef-enhanced meals | Arm Label: choice architecture; Type: EXPERIMENTAL; Interventions: Behavioral: choice architecture | Arm Label: Chef and choice architecture; Type: EXPERIMENTAL; Interventions: Behavioral: choice architecture, Other: Chef-enhanced meals | Intervention Type: BEHAVIORAL; Name: choice architecture; Assigned to Arm(s): Chef and choice architecture, choice architecture | Intervention Type: OTHER; Name: Chef-enhanced meals; Assigned to Arm(s): Chef, Chef and choice architecture
D: Arm Label: Feedback only; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback letters | Arm Label: Feedback plus incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback plus incentives | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feedback letters; Assigned to Arm(s): Feedback only | Intervention Type: BEHAVIORAL; Name: Feedback plus incentives; Assigned to Arm(s): Feedback plus incentives

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intratumoral Genetic Therapy for Lung Cancer
Brief Summary: The purpose of this study is to determine the dose that the vaccine can be given safely to patients when injected directly into the lung tumor, without any serious side effects.


Options:
A: Arm Label: Tecemotide (L-BLP25); Type: EXPERIMENTAL; Interventions: Biological: Tecemotide (L-BLP25), Drug: Single low dose cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Tecemotide (L-BLP25); Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Tecemotide (L-BLP25) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: autologous dendritic cell adenovirus CCL21 vaccine | Intervention Type: BIOLOGICAL; Name: autologous dendritic cell adenovirus CCL21 vaccine; Assigned to Arm(s): Arm 1
C: Arm Label: Melanoma - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: RCC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: mCRPC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: NSCLC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Arm Label: CRC - BMS-936558 (MDX-1106); Type: EXPERIMENTAL; Interventions: Biological: BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): Melanoma - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): RCC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): mCRPC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): NSCLC - BMS-936558 (MDX-1106) | Intervention Type: BIOLOGICAL; Name: BMS-936558 (MDX-1106); Assigned to Arm(s): CRC - BMS-936558 (MDX-1106)
D: Arm Label: MEDI4736; Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Other: PLACEBO | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): MEDI4736 | Intervention Type: OTHER; Name: PLACEBO; Assigned to Arm(s): PLACEBO

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Odense Overweight Intervention Study (OOIS): A Randomized Controlled Trial on Overweight Prevention in Children.
Brief Summary: Strong and consistent evidence have shown that overweight, including obesity, is an important risk factor for the development of cardiovascular disease (CVD) in adults. Several studies have found an association between overweight in childhood and increased risk of morbidity and mortality later in life. The prevalence of overweight in children and adolescents has increased in recent years, and consequently it is important to identify effective approaches in the prevention and treatment of overweight in young individuals.

Approaches such as resident weight loss camps have shown promising results. A residential camp setting provides an opportunity to increase and control exposure to, for instance, particular foodstuffs, beverages and physical activity opportunities. However, well-designed studies with sufficient participants are still needed on the reversal of overweight in childhood with increased focus on documenting predictors of behavior changes associated with decreases in overweight.

This study is carried through as a randomized controlled trial which investigates the effect of participating in a 6 week health promoting resident for overweight fifth grade children camp followed by 46 weeks of family support.

The study hypothesis is that participating in a 6 week resident camp and a following period of 46 weeks of child and family support will induce a reduction in body mass index (BMI). In addition it is expected that the intensity and duration intervention program is sufficient to cause changes in physiological parameters related to a reduced risk of lifestyle diseases.


Options:
A: Arm Label: NewNordicDiet first; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Arm Label: NewNordicDiet last; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Intervention Type: OTHER; Name: School meals based on the principles of the New Nordic Diet; Assigned to Arm(s): NewNordicDiet first, NewNordicDiet last
B: Intervention Type: BEHAVIORAL; Name: Switch active lifestyles brought to you by MediaWise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Switch active lifestyles from MediaWise; Assigned to Arm(s): N/A
C: Arm Label: Intervention camp; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention camp | Arm Label: Small intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Small intervention | Intervention Type: BEHAVIORAL; Name: Small intervention; Assigned to Arm(s): Small intervention | Intervention Type: BEHAVIORAL; Name: Intervention camp; Assigned to Arm(s): Intervention camp
D: Arm Label: "Fortaleça sua Saúde" program; Type: EXPERIMENTAL; Interventions: Behavioral: "Fortaleça sua Saúde" program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: "Fortaleça sua Saúde" program; Assigned to Arm(s): "Fortaleça sua Saúde" program

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Odense Overweight Intervention Study (OOIS): A Randomized Controlled Trial on Overweight Prevention in Children.
Brief Summary: Strong and consistent evidence have shown that overweight, including obesity, is an important risk factor for the development of cardiovascular disease (CVD) in adults. Several studies have found an association between overweight in childhood and increased risk of morbidity and mortality later in life. The prevalence of overweight in children and adolescents has increased in recent years, and consequently it is important to identify effective approaches in the prevention and treatment of overweight in young individuals.

Approaches such as resident weight loss camps have shown promising results. A residential camp setting provides an opportunity to increase and control exposure to, for instance, particular foodstuffs, beverages and physical activity opportunities. However, well-designed studies with sufficient participants are still needed on the reversal of overweight in childhood with increased focus on documenting predictors of behavior changes associated with decreases in overweight.

This study is carried through as a randomized controlled trial which investigates the effect of participating in a 6 week health promoting resident for overweight fifth grade children camp followed by 46 weeks of family support.

The study hypothesis is that participating in a 6 week resident camp and a following period of 46 weeks of child and family support will induce a reduction in body mass index (BMI). In addition it is expected that the intensity and duration intervention program is sufficient to cause changes in physiological parameters related to a reduced risk of lifestyle diseases.


Options:
A: Arm Label: Lifestyle modification; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Healthy Kids-Houston program | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Healthy Kids-Houston program; Assigned to Arm(s): Lifestyle modification | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Intervention camp; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention camp | Arm Label: Small intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Small intervention | Intervention Type: BEHAVIORAL; Name: Small intervention; Assigned to Arm(s): Small intervention | Intervention Type: BEHAVIORAL; Name: Intervention camp; Assigned to Arm(s): Intervention camp
C: Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A
D: Arm Label: NewNordicDiet first; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Arm Label: NewNordicDiet last; Type: OTHER; Interventions: Other: School meals based on the principles of the New Nordic Diet | Intervention Type: OTHER; Name: School meals based on the principles of the New Nordic Diet; Assigned to Arm(s): NewNordicDiet first, NewNordicDiet last

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy
Brief Summary: The purpose of this study is to determine the safety and efficacy of PDT at 30% verteporfin dose in the treatment of CSC.


Options:
A: Arm Label: Selective Retinatherapy (SRT); Type: EXPERIMENTAL; Interventions: Device: Selective Retina Therapy (SRT) | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: crossover; Type: EXPERIMENTAL; Interventions: Device: Selective Retina Therapy (SRT) | Intervention Type: DEVICE; Name: Selective Retina Therapy (SRT); Assigned to Arm(s): Selective Retinatherapy (SRT), crossover
B: Arm Label: 50% dose PDT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PDT | Arm Label: 30% dose PDT; Type: EXPERIMENTAL; Interventions: Procedure: PDT | Intervention Type: PROCEDURE; Name: PDT; Assigned to Arm(s): 30% dose PDT, 50% dose PDT
C: Arm Label: Intravitreal Aflibercept Injection (x4); Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Aflibercept Injection | Arm Label: Intravitreal Aflibercept Injection (x6); Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Aflibercept Injection | Intervention Type: DRUG; Name: Intravitreal Aflibercept Injection; Assigned to Arm(s): Intravitreal Aflibercept Injection (x4), Intravitreal Aflibercept Injection (x6)
D: Arm Label: Half-dose photodynamic therapy (PDT); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Half-dose photodynamic therapy (PDT) | Arm Label: Micropulse laser (ML) treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Micropulse laser (ML) treatment | Intervention Type: PROCEDURE; Name: Half-dose photodynamic therapy (PDT); Assigned to Arm(s): Half-dose photodynamic therapy (PDT) | Intervention Type: PROCEDURE; Name: Micropulse laser (ML) treatment; Assigned to Arm(s): Micropulse laser (ML) treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Non-treatment Follow-up For Cardiac Assessments Following Use Of Smoking Cessation Treatments In Subjects With And Without A History Of Psychiatric Disorders
Brief Summary: Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data collection.


Options:
A: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline + Active Tailored Dose; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline + Placebo Tailored Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Tailored Dose | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Tailored Dose, Varenicline + Placebo Tailored Dose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Non-treatment Follow-up For Cardiac Assessments Following Use Of Smoking Cessation Treatments In Subjects With And Without A History Of Psychiatric Disorders
Brief Summary: Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data collection.


Options:
A: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
C: Arm Label: INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING; Type: EXPERIMENTAL; Interventions: Behavioral: Mediterranean diet counseling | Arm Label: CONTROL GROUP: WITHOUT CHANGES IN DIET; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mediterranean diet counseling; Assigned to Arm(s): INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING
D: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Non-treatment Follow-up For Cardiac Assessments Following Use Of Smoking Cessation Treatments In Subjects With And Without A History Of Psychiatric Disorders
Brief Summary: Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data collection.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
B: Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nicotine patch, nicotine inhaler, bupropion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch | Intervention Type: DRUG; Name: Nicotine patch, nicotine inhaler, bupropion; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): 2
D: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Patch | Arm Label: Placebo Patch and Placebo Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Patch and Placebo Pill | Arm Label: Delayed-quit control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch | Intervention Type: DRUG; Name: Placebo Patch and Placebo Pill; Assigned to Arm(s): Placebo Patch and Placebo Pill

Answer: B